Risk of Thromboembolic Events and Major Adverse Cardiovascular Events Following Antivascular Endothelial Growth Factor Therapy in Patients with Colorectal Cancer

SIMPLE SUMMARY: We assessed whether anti-VEGF therapy increases the risk of thromboembolic events or major adverse cardiovascular events (MACEs) in patients with colorectal cancer based on real-world evidence. Patients with advanced colorectal cancer who had previously received anti-VEGF therapy did...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yen-Cheng, Yeh, Liang-Tsai, Yang, Shun-Fa, Chou, Ming-Chih, Huang, Jing-Yang, Yeh, Chao-Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817700/
https://www.ncbi.nlm.nih.gov/pubmed/36612005
http://dx.doi.org/10.3390/cancers15010009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817700/
https://www.ncbi.nlm.nih.gov/pubmed/36612005
http://dx.doi.org/10.3390/cancers15010009

Ejemplares similares